Amisulpride, a dopamine D2/D3-antagonist, prevents chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic cisplatin or anthracycline-cyclophosphamide regimens: A randomised, double-blind, placebo-controlled, dose-ranging trial

被引：0
|
作者：
Herrstedt, J. [1 ]
Summers, Y. [2 ]
Jordan, K. [3 ]
Von Pawel, J. [4 ]
Jakobsen, A. H. [5 ]
Ewertz, M. [1 ]
Chan, S. [6 ]
Naik, J. [7 ]
Karthaus, M. [8 ]
Dubey, S. [9 ]
Davis, R. [10 ]
Fox, G. [11 ]
机构：
[1] Odense Univ Hosp, Oncol, DK-5000 Odense, Denmark
[2] Univ S Manchester Hosp, Pulm Oncol Unit, Manchester M20 8LR, Lancs, England
[3] Univ Klinikum Halle Saale, Dept Oncol Haematol, Halle An Der Saale, Germany
[4] Asklepios Fachkliniken, Klin Pneumol, Munich, Germany
[5] Herlev Hosp, Dept Oncol, Copenhagen, Denmark
[6] Univ Nottingham Hosp, Acad Unit Oncol, Nottingham NG7 2UH, England
[7] Mid Yorkshire NHS Trust, Oncol, Wakefield, England
[8] Klinikum Neuperlach, Klin Hamatol Onkol & Palliativmed, Munich, Germany
[9] Derriford Hosp, Dept Oncol, Plymouth PL6 8DH, Devon, England
[10] Wexham Pk Hosp, Canc Clin Trials Off, Slough SL2 4HL, Berks, England
[11] Acacia Pharma Ltd, Clin Dev, Cambridge, England
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30662-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1573
引用
收藏
页码：S228 / S229
页数：2
相关论文
共 44 条
  • [1] Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial
    J. Herrstedt
    Y. Summers
    K. Jordan
    J. von Pawel
    A. H. Jakobsen
    M. Ewertz
    S. Chan
    J. D. Naik
    M. Karthaus
    S. Dubey
    R. Davis
    G. M. Fox
    Supportive Care in Cancer, 2019, 27 : 2699 - 2705
  • [2] Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial
    Herrstedt, J.
    Summers, Y.
    Jordan, K.
    von Pawel, J.
    Jakobsen, A. H.
    Ewertz, M.
    Chan, S.
    Naik, J. D.
    Karthaus, M.
    Dubey, S.
    Davis, R.
    Fox, G. M.
    SUPPORTIVE CARE IN CANCER, 2019, 27 (07) : 2699 - 2705
  • [3] Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double-blind, placebo-controlled trial
    Navari, Rudolph M.
    Qin, Rui
    Ruddy, Kathryn Jean
    Liu, Heshan
    Powell, Steven Francis
    Bajaj, Madhuri
    Dietrich, Leah L.
    Lafky, Jacqueline M.
    Loprinzi, Charles L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)
  • [4] Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study
    Mizukami, Naomi
    Yamauchi, Masanori
    Koike, Kazuhiko
    Watanabe, Akihiko
    Ichihara, Koji
    Masumori, Naoya
    Yamakage, Michiaki
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2014, 47 (03) : 542 - 550
  • [5] A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin
    Bossi, P.
    Cortinovis, D.
    Fatigoni, S.
    Rocca, M. Cossu
    Fabi, A.
    Seminara, P.
    Ripamonti, C.
    Alfieri, S.
    Granata, R.
    Bergamini, C.
    Agustoni, F.
    Bidoli, P.
    Nole, F.
    Pessi, M. A.
    Macchi, F.
    Michellini, L.
    Montanaro, F.
    Roila, F.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2547 - 2551
  • [6] Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study
    Bergamini, C.
    Bergamini, C.
    Cortinovis, D.
    Fatigoni, S.
    Rocca, M. Cossu
    Fabi, A.
    Iannace, A.
    Emiliani, A.
    Pessi, M. A.
    Ripamonti, C. I.
    Alfieri, S.
    Granata, R.
    Agustoni, F.
    Bidoli, P.
    Roila, F.
    Nole, F.
    Macchi, F.
    Michellini, L.
    Montanaro, F.
    Bossi, P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy
    Sugawara, Shunichi
    Inui, Naoki
    Kanehara, Masashi
    Morise, Masahiro
    Yoshimori, Kozo
    Kumagai, Toru
    Fukui, Tomoya
    Minato, Koichi
    Iwashima, Akira
    Takeda, Yuichiro
    Kubota, Kaoru
    Saeki, Toshiaki
    Tamura, Tomohide
    CANCER, 2019, 125 (22) : 4076 - 4083
  • [8] Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial
    Grunberg, Steven M.
    Rolski, Janusz
    Strausz, Janos
    Aziz, Zeba
    Lane, Stephen
    Russo, Mark W.
    Wissel, Paul
    Guckert, Mary
    Wright, Oliver
    Herrstedt, Jorn
    LANCET ONCOLOGY, 2009, 10 (06): : 549 - 558
  • [9] Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial
    Schwartzberg, Lee S.
    Modiano, Manuel R.
    Rapoport, Bernardo L.
    Chasen, Martin R.
    Gridelli, Cesare
    Urban, Laszlo
    Poma, Allen
    Arora, Sujata
    Navari, Rudolph M.
    Schnadig, Ian D.
    LANCET ONCOLOGY, 2015, 16 (09): : 1071 - 1078
  • [10] Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
    Saito, H.
    Yoshizawa, H.
    Yoshimori, K.
    Katakami, N.
    Katsumata, N.
    Kawahara, M.
    Eguchi, K.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 1067 - 1073
12345